Prospective Cohort of Acute Cardiology Referrals in an Ambulatory Day-Hospital Setting (CESAR)
CESAR Study: Prospective Cohort of Consecutive Patients Undergoing Cardiologic Evaluation in a Specialized Ambulatory Referral Unit
Suspected acute or subacute cardiovascular diseases-including chest pain, dyspnea, and palpitations-are among the most common reasons for unscheduled emergency department visits and pre-hospital referrals. Despite this high clinical burden, the diagnostic yield is often limited, with a frequent mismatch between initial clinical suspicion and final diagnosis, contributing to substantial healthcare utilization and hospitalization rates. Current evidence is largely focused on specific conditions such as acute coronary syndromes, heart failure, arrhythmias, or pulmonary embolism, and rarely integrates the full spectrum of clinical, biological, and imaging data obtained during initial evaluation.
To address this gap, we will establish a prospective cohort of all consecutive patients referred to the ambulatory day-hospital cardiology unit at Lariboisière University Hospital. This unit acts as a specialized downstream referral structure within the emergency care pathway, receiving patients after triage by emergency physicians, pre-hospital regulation services (SAMU), mobile intensive care units (SMUR), or emergency departments. Although it does not capture all suspected cardiovascular emergencies, it represents a selected real-world population deemed to require specialized acute cardiology assessment.
The primary objective is to assess the frequency of cardiac conditions diagnosed in this cohort. Secondary objectives include characterization of patient profiles and diagnostic pathways; evaluation of the diagnostic and prognostic performance of clinical, biological, imaging, and multimodal parameters using final Heart Team diagnosis as reference; analysis of prior health history and healthcare utilization; and assessment of the medico-economic burden of suspected acute cardiovascular disease. The study will further support the development of a dedicated biobank and the validation of next-generation biomarkers, including AI-driven and voice-based markers, as well as decision-support algorithms for binary classification of cardiac involvement. Through integration of multimodal data and linkage with national health records, this approach aims to improve diagnostic accuracy, risk stratification, and understanding of the healthcare impact of acute cardiovascular presentations in a real-world setting.
연구 개요
상태
상태
정황
정황
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Théo PEZEL, MD, PhD
- 전화번호: +33 1 49 95 8224
- 이메일: theo.pezel@aphp.fr
연구 연락처 백업
- 이름: Julien HUDELO, MD
- 이메일: juhudelo@gmail.com
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- The study will include all consecutive patients referred to ambulatory day-hospital unit for suspicion of acute or sub-acute cardiovascular disease at the Cardiology Department of Lariboisière University Hospital.
Exclusion Criteria:
- Patient unable to provide informed consent
- Patient not affiliated to French social security
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Proportion of patients with confirmed cardiovascular diagnosis among consecutive patients consulting for suspicion of acute or sub-acute cardiovascular disease at the ambulatory day-hospital unit.
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion referred to cardiac computed tomography (CCT)
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to cardiovascular magnetic resonance (CMR)
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to stress tests.
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to Holter monitoring or implantable loop recorders
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion with introduction of heart failure (HF) therapy
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion with introduction of anti-platelet therapy
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion with introduction of anti-coagulant therapy
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to percutaneous coronary intervention (PCI)
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to cardiac surgery
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to electrical cardioversion
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to catheter ablation
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to pacemaker implantation
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to defibrillator implantation
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Diagnostic performance of each initial parameter with: sensitivity, specificity, positive predictive value, negative predictive value, and area under the ROC curve.
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Cost of care pathways initial and up to 2-5 years
기간: From enrollement to five years of follow-up.
|
From enrollement to five years of follow-up.
|
|
|
Prognostic value of baseline features to predict medical events annually up to 10 years of follow-up
기간: From enrollement to ten years of follow-up.
|
The occurrence of:
n. Electrophysiological studies (catheter ablation, pacemaker / defibrillator implantation...) |
From enrollement to ten years of follow-up.
|
|
Cost-effectiveness of the CESAR care pathway
기간: From enrollement to five years of follow-up.
|
Cost-effectiveness of the CESAR care pathway compared with a propensity score-matched control population extracted from the French national health claims database.
|
From enrollement to five years of follow-up.
|
|
F1 score of the artificial intelligence model for detecting cardiac involvement
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Prognostic value of voice-derived acoustic and speech parameters
기간: At enrollement (D0).
|
The occurrence of: a. All-cause mortality b.
Cardiovascular mortality c.
Sudden cardiac death d.
Hospitalization for any cardiovascular reason and duration of hospitalization
|
At enrollement (D0).
|
|
Number of sick leave
기간: From enrollement to five years of follow-up.
|
From enrollement to five years of follow-up.
|
|
|
Five-year event-free survival
기간: From enrollement to five years of follow-up.
|
Event-free survival in patients managed through the CESAR care pathway compared with a propensity score-matched control population extracted from the French national health claims database.
|
From enrollement to five years of follow-up.
|
|
Area under the precision-recall curve (PR-AUC) of the artificial intelligence model for detecting cardiac involvement
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Area under the receiver operating characteristic curve (ROC-AUC) of the artificial intelligence model for detecting cardiac involvement
기간: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Duration of sick leave
기간: From enrollement to five years of follow-up.
|
Cumulative duration of sick leave during follow-up in days.
|
From enrollement to five years of follow-up.
|
공동 작업자 및 조사자
협력자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- APHP260122
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .